How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Lilly is looking for opportunities in Diabetes

Organization name

Global External Research & Development Lilly Research Laboratories Eli Lilly and Company

Profile

Diabetes

The vision at Lilly Research Laboratories, of which Global External R&D is a part, is a commitment to discovering, developing and acquiring innovative medicines to improve outcomes for individual patients.

Lilly was one of the pioneers of diabetes care, manufacturing the first vials of Insulin for patients with diabetes. Today, they remain competitive with innovative treatment options, having a portfolio of commercially successful products and promising pipeline opportunities. They're collaborating with others to bring improved treatment options to a growing population of patients with diabetes.

They are particularly interested in:

  • Biologicals or orals "Glucose plus" agents that lower HbA1c and aid weight loss or reduce cardiovascular risk factors ( lower blood pressure, raise HDL, lower LDL, etc.)
  • Therapies with human efficacy data that slow or reverse diabetic complications, e.g., diabetic nephropathy
  • Novel insulin sensitizers, secretagogues or best-in-class agents
  • Targets/pathways that have the potential to affect multiple underlying defects.
  • Therapies for the treatment of endocrine diseases with an unmet medical need

Pathway priortities:

  • Improve Insulin secretion /beta cell related biomarkers
  • Islet health, beta cell protection
  • Lower insulin resistance
  • Lower hepatic glucose output

Currently out of scope

  • Nutraceuticals

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries